NOVA MENTIS Life Science Corp. is a Canadian-based public company whose focus is to build and support a diversified portfolio of health and wellness businesses.
Pilz Bioscience Corp. (“Pilz”), which has signed a non-binding letter of intent to be acquired by Nova Mentis, is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD). The company intends to leverage a unique systems-level scientific approach that integrates inflammation, oral/gut/brain axis, and behavior. Pilz aims to lead the global effort in design of effective and comprehensive diagnostic/monitoring programs and first-in-class therapeutics.
The Pilz integrative approach is to develop a diagnostic and therapeutic index for conditions with unmet medical needs. Pilz scientists are building a platform that integrates genetic risk factors, inflammatory/immune indices, and microbiome data into a computational model.
Initially targeting Autism Spectrum Disorders (ASD), Pilz is developing the ‘ASD Correlate’ – a statistical score for modeling diagnostics and therapeutics. Explore the ASD Correlate
Focusing on chronic neuro-inflammatory conditions, Pilz Bioscience is developing a robust, diversified pipeline in multiple indications with high unmet medical needs. The initial target indication is Autism Spectrum Disorder (ASD).